SEARCH

SEARCH BY CITATION

References

  • 1
    Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 47985.
  • 2
    Quint LE, Francis IR, Wahl RL, Gross BH. Imaging of Lung Cancer: Lung Cancer, Principles and Practice. Philadelphia: Lippincott-Raven, 1996; 43770.
  • 3
    Kenzaki K, Sakiyama S, Tomimoto H et al. Clinical analysis of elderly patients with primary lung cancer. Kyobu Geka 2010;63: 51923; discussion 524–6.
  • 4
    Goya T, Asamura H, Yoshimura H et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005; 50: 22734.
  • 5
    Mountain CF. A new international staging system for lung cancer. Chest 1986; 4(Suppl): 225S33S.
  • 6
    Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009; 471: 46986.
  • 7
    Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 171823.
  • 8
    Sullivan FJ. Palliative Radiotherapy for Lung Cancer: Lung Cancer, Principles and Practice. Philadelphia: Lippincott-Raven, 1996; 77589.
  • 9
    Portoukalian J, Zwingelstein G, Dore JF, Bourgoin JJ. Studies of a ganglioside fraction extracted from human malignant melanoma. Biochimie 1976; 58: 12857.
  • 10
    Akasako Y, Nara K, Nagai Y, Hashimoto Y. Inhibition of ganglioside synthesis reduces the neuronal survival activity of astrocytes. Neurosci Lett 2011; 488: 199203.
  • 11
    Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991; 67: 302935.
  • 12
    Laferte S, Fukuda MN, Fukuda M, Dell A, Dennis JW. Glycosphingolipids of lectin-resistant mutants of the highly metastatic mouse tumor cell line, MDAY-D2. Cancer Res 1987; 47: 1509.
  • 13
    Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Kawano T, Sone S. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Int J Cancer 1998; 78: 4805.
  • 14
    Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Sone S. Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes. Jpn J Cancer Res 1996; 87: 497504.
  • 15
    Fukumoto H, Nishio K, Ohta S, Hanai N, Saijo N. Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody. Int J Cancer 1996; 67: 67680.
  • 16
    Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Miki T, Sone S. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966. Clin Exp Metastasis 2000; 18: 35360.
  • 17
    Langerak A, River G, Mitchell E, Cheema P, Shing M. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer 2009; 8: 4954.
  • 18
    Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007; 6: 52931.
  • 19
    Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park) 2006; 20:137382; discussion 1382, 1392–4, 1397.
  • 20
    Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007; 18: 9634.
  • 21
    Ura T. The current status of development of anti-EGFR antibodies. Gan To Kagaku Ryoho 2010; 37: 77781.
  • 22
    Shitara K. Potelligent antibodies as next generation therapeutic antibodies. Yakugaku Zasshi 2009; 129: 39.
  • 23
    Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor β chain monoclonal antibody in mice. J Exp Med 1993; 178: 11037.
  • 24
    Nishioka Y, Yano S, Fujiki F et al. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int J Cancer 1997; 71: 1707.
  • 25
    Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 1984; 70: 25768.
  • 26
    Yano S, Nishioka Y, Izumi K et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996; 67: 2117.
  • 27
    Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007; 18: 9634.
  • 28
    Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100: 156672.
  • 29
    Klehr M, Koehl U, Mühlenhoff M et al. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC). J Immunother 2009; 32: 44251.